Clinical and experimental studies have shown that EGFR/ErbB1 inhibitors can relieve neuropathic and breast cancer-related pain (Kaufman et al., 2010; Kersten and Cameron, 2012; Kersten et al., 2013, 2015, 2019; Martin et al., 2017; Wang et al., 2019). Here, EGFR is linked to breast cancer.